<DOC>
	<DOC>NCT00409773</DOC>
	<brief_summary>A 6-week clinical trial in patients with metabolic syndrome and hypercholesterolemia at high risk for coronary heart disease to study the effects of ezetimibe/simvastatin and atorvastatin on lipids.</brief_summary>
	<brief_title>Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED)</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe, Simvastatin Drug Combination</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Patients 18 to 79 years of age with metabolic syndrome and hypercholesterolemia at high risk for coronary heart disease (CHD) with LDLC above 70 mg/dL or 100 mg/dL depending on their CHD risk category A condition which, in the opinion of the investigator, pose a risk to the patient or interfere with participating in the study Patient is likely to be greater than 20% noncompliant in taking study medications Patients with chronic medical conditions Patients with unstable doses of medications Pregnant or lactating women, women intending to become pregnant Patient is currently receiving prescription therapy with statins or other lipidaltering medications Patient with Type 1 or Type 2 diabetes mellitus that is poorly controlled, newly diagnosed, or is taking new or recently adjusted antidiabetic pharmacotherapy (with the exception of +/ 10 units of insulin)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>